体外细胞转化试验的研究与应用进展

doi:10.3969/j.issn.1004-616x.2018.04.013

癌变·畸变·突变 ›› 2018, Vol. 30 ›› Issue (4): 310-314.doi: 10.3969/j.issn.1004-616x.2018.04.013

体外细胞转化试验的研究与应用进展

王丹^1,2, 耿兴超², 李波², 王雪², 文海若²

1. 中国药科大学中药学院, 江苏南京 211198;
2. 中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全性评价研究北京市重点试验室, 北京 100176

收稿日期:2017-08-01 修回日期:2018-06-07 出版日期:2018-07-30 发布日期:2018-07-30
通讯作者: 王雪,E-mail:xue_wang@nifdc.org.cn;文海若,E-mail:wenhairuo@nifdc.org.cn E-mail:xue_wang@nifdc.org.cn;wenhairuo@nifdc.org.cn
作者简介:王丹,E-mail:wangdandali@163.com
基金资助:
国家“重大新药创制”科技重大专项（2015ZX09501004-002）

Received:2017-08-01 Revised:2018-06-07 Online:2018-07-30 Published:2018-07-30

摘要/Abstract

摘要： 细胞转化试验（CTAs）是利用体外培养的动物细胞模拟致癌物的体内致癌作用，从而进行致癌物检测的一种技术。它可以在不考虑致癌机制的情况下衡量化学物的致癌能力，能够满足对潜在致癌物致癌能力预测的需求。与动物试验相比，CTAs既可以充分反映细胞与致癌物之间的相互作用，也明显缩短了试验周期，减少了动物的使用。通过不断地对方法进行优化和改良，已形成更为客观准确的CTAs细胞转化灶判定标准，其必将在临床前致癌性早期评价中发挥日益重要的作用。本文就CTAs的背景、优化、影响因素、国际发展趋势等方面进行综述，为今后CTAs的应用提供借鉴。

关键词: 细胞转化试验, 致癌性, 非遗传毒性致癌物, 叙利亚地鼠胚胎细胞, Bhas 42细胞

中图分类号:

R965.3

王丹, 耿兴超, 李波, 王雪, 文海若. 体外细胞转化试验的研究与应用进展[J]. 癌变·畸变·突变, 2018, 30(4): 310-314.

参考文献

[1] REBECCA L S,KIMBERLY D M,AHMEDIN J. Cancer statistics,2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[2] ICH. S1A:Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals[EB/OL].[1995-11-29]. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S1A/Step4/S1A_Guideline.pdf
[3] FDA. Guidance for Industry Statistical Aspects of the Design,Analysis,and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals[EB/OL].[2001-04-23]. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079272.pdf
[4] CRETON S,AARDEMA M J,CARMICHAEL P L,et al. Cell transformation assays for prediction of carcinogenic potential:state of the science and future research needs[J]. Mutagenesis,2012,27(1):93-101.
[5] EC. Corrigendum to Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration,Evaluation,Authorisation and Restriction of Chemicals (REACH),establishing a European Chemicals Agency,amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC,93/67/EEC,93/105/EC and 2000/21/EC[EB/OL].[2006-12-30]. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2007.136.01.0003.01.ENG&toc=OJ:L:2007:136:TOC
[6] BERWALD Y,SACHS L E O. In vitro cell transformation with chemical carcinogens[J]. Nature,1963,200(4912):1182-1184.
[7] KERCKAERT G A,ISFORT R J,CARR G J,et al. A comprehensive protocol for conducting the Syrian hamster embryo cell transformation assay at pH 6.70[J]. Mutat Res,1996,356(1):65-84.
[8] AARONSON S A,TODARO G J. Basis for the acquisition of malignant potential by mouse cells cultivated in vitro[J]. Science,1968,162(3857):1024-1026.
[9] SASAKI K,UMEDA M,SAKAI A,et al. Transformation Assay in Bhas 42 cells:a model using initiated cells to study mechanisms of carcinogenesis and predict carcinogenic potential of chemicals[J]. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev,2015,33(1):1-35.
[10] ISFORT R J,LEBOEUF R A. Application of in vitro cell transformation assays to predict the carcinogenic potential of chemicals[J]. Mutat Res,1996,365(1):161-173.
[11] PANT K,SLY J E,BRUCE S W,et al. Syrian hamster embryo (SHE) cell transformation assay with and without X-ray irradiation of feeder cells using Di(2-ethylhexyl)phthalate (DEHP) and N-nitroso-N-methylnitroguanidine (MNNG)[J]. Mutat Res,2010,698(1/2):6-10.
[12] SCHECHTMAN L M. Metabolic activation of procarcinogens by subcellular enzyme fractions in the C3H 10T1/2 and BALB/c 3T3 cell transformation systems[J]. IARC Sci Publ,1985,67:137-162.
[13] AHMADZAI A A,TREVISAN J,PANG W,et al. Classification of agents using Syrian hamster embryo (SHE) cell transformation assay (CTA) with ATR-FTIR spectroscopy and multivariate analysis[J]. Mutagenesis,2015,30(5):603-612.
[14] STAMPFER M R,YASWEN P. Human epithelial cell immortalization as a step in carcinogenesis[J]. Cancer Lett,2003,194(2):199-208.
[15] MATTHEWS E J I. Investigation of experimental parameters that influence detection of spontaneous transformation[J]. Environ Health Perspect,2013,101(Sup 2):277-291.
[16] SAKAI A. Orthovanadate,an inhibitor of protein tyrosine phosphatases,acts more potently as a promoter than as an initiator in the BALB/3T3 cell transformation[J]. Carcinogenesis,1997,18(7):1395-1399.
[17] HOFFMANN S,HOTHORN L A,EDLER L,et al. Two new approaches to improve the analysis of BALB/c 3T3 cell transformation assay data[J]. Mutat Res,2012,744(1):36-41.
[18] KAJIWARA Y,AJIMI S,HOSOKAWA A,et al. Improvement of carcinogen detection in the BALB/3T3 cell transformation assay by using a rich basal medium supplemented with low concentration of serum and some growth factors[J]. Mutat Res Genet Toxicol Environ Mutagen,1997,393(1/2):81-90.
[19] BOBERG D R,BATISTELA M S,PECHARKI M,et al. Copy number variation in ACHE/EPHB4(7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer[J]. Chem Biol Interact,2013,203(1):344-347.
[20] POTH A,HEPPENHEIMER A,BOHNENBERGER S. Bhas42 cell transformation assay as a predictor of carcinogenicity[J]. Aatex,2006,14(Sup 1):519-521.
[21] SASAKI K. A method for selecting mammal transformed cells:EP20090169631[P/OL]. 2009-09-07[2011-08-17]. http://www.freepatentsonline.com/EP2163895B1.html.
[22] 王颖. Bhas42细胞转化试验方法学及其应用研究[D]. 北京:中国食品药品检定研究院,2013.
[23] SASAKI K,CHIDA K,HASHIBA H,et al. Enhancement by 1 alpha,25-dihydroxyvitamin D3 of chemically induced transformation of BALB 3T3 cells without induction of ornithine decarboxylase or activation of protein kinase C1[J]. Cancer Res,1986,46(2):604-610.
[24] SASAKI K,BOHNENBERGER S,HAYASHI K,et al. Recommended protocol for the BALB/c 3T3 cell transformation assay[J]. Mutat Res Genet Toxicol Environ Mutagen,2012,744(1):30-35.
[25] ECVAM. EURL ECVAM Recommendation on the Cell Transformation Assay based on the Bhas 42 cell line[EB/OL].[2013-12-7]. https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-recommendations/eurl-ecvam-recommendation-on-the-cell-transformation-assay-based-on-the-bhas-42-cell-line
[26] 郑晓彤,陈薛钗,贺帅,等. 体外细胞转化的应用及其影响因素[J]. 生命科学仪器,2015,13(4):17-20.
[27] SAKAI A,SASAKI K,MURAMATSU D,et al. A Bhas 42 cell transformation assay on 98 chemicals:the characteristics and performance for the prediction of chemical carcinogenicity[J]. Mut Res,2010,702(1):100-122.
[28] 庞雅琴,陈雯. 体外细胞转化试验研究进展[J]. 癌变·畸变·突变,2007,19(6):511-514.
[29] 刘家仁,庞永珣,张尤恩,等. 用细胞转化实验检测S江有机污染致癌危险性[J]. 癌变·畸变·突变,1999,11(4):194-198.
[30] OECD. Draft test guideline in vitro carcinogenicity:Bhas 42 cell transformation assay[EB/OL].[2013-9-11]. http://www.oecd.org/env/ehs/testing/Bhas_42_CTA_TG_HRI_Draft_Rev_7.pdf

体外细胞转化试验的研究与应用进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	敬海明, 李国君, 宁钧宇. 苯丙(a)蒽的毒性研究进展[J]. 癌变·畸变·突变, 2021, 33(2): 149-152.
[2]	阎晓丹, 李烨, 叶向锋, 林小琪, 单永超, 魏金锋, 王爱平. 氧化钴的毒性评价及其作为医用材料的研究进展[J]. 癌变·畸变·突变, 2015, 27(4): 323-324,328.
[3]	王颖, 蒲江, 齐乃松, 文海若, 王欣, 胡燕平, 宋捷, 张海洲, 王雪. Bhas 42细胞转化试验高通量检测方法的建立及应用[J]. 癌变·畸变·突变, 2015, 27(4): 288-293.
[4]	鞠莉，朱丽瑾，杨军. 多壁碳纳米管致癌性的研究进展[J]. 癌变·畸变·突变, 2014, 26(3): 239-240.
[5]	徐新云，刘月峰，易娟，周丽，黄新凤，毛吉炎，毛侃琅. 三氯乙烯药疹样皮炎病人外周血c-fos、c-myc、K-ras和p53 mRNA表达水平的研究[J]. , 2012, 24(1): 56-59.
[6]	武红叶(综述)；曾　明(审校). 六价铬致癌机制的研究进展[J]. , 2006, 18(6): 491-493.
[7]	雷毅雄;陈学敏;陈家. 反义翻译延伸因子TEF-1δ对氯化镉致癌性的逆转作用[J]. , 2005, 17(1): 1-3.
[8]	刘家仁1 　庞永王旬1 　张尤恩1 　范　春1 　王贤珍1 　朱振岗1 　E. J . Love2. 用细胞转化实验检测S 江有机污染致癌危险性[J]. , 1999, 11(4): 194-198.